Back

COMBINATION EFFECT OF FINERENONE AND EMPAGLIFLOZIN IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES USING A UACR ENDPOINT STUDY (CONFIDENCE)—BASELINE CHARACTERISTICS

Abstract Title *

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than January 23, 2025. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

First Name *

Rajiv

Last Name *

Agarwal

Number of Co-Authors

Co-author 1

Jennifer B. Green
Jennifer.Green@Duke.edu
Duke University School of Medicine
Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute
Durham
United States

Co-author 2

Hiddo J.L. Heerspink
h.j.lambers.heerspink@umcg.nl
University Medical Centre Groningen
Department of Clinical Pharmacy and Pharmacology
Groningen
Netherlands

Co-author 3

Johannes F.E. Mann
prof.j.mann@googlemail.com
KfH Kidney Centre Munich and Friedrich Alexander University
Department of Nephrology & Hypertension
Munchen
Germany

Co-author 4

Janet B. McGill
jmcgill@wustl.edu
Washington University in St. Louis
Division of Endocrinology, Metabolism & Lipid Research, John T. Milliken Department of Internal Medicine
St. Louis
United States

Co-author 5

Amy K. Mottl
amy_mottl@med.unc.edu
UNC School of Medicine
University of North Carolina Kidney Center
Chapel Hill
United States

Co-author 6

Julio Rosenstock
juliorosenstock@dallasdiabetes.com
Velocity Clinical Research at Medical City
Senior Scientific Advisor
Dallas
United States

Co-author 7

Peter Rossing
peter.rossing@regionh.dk
Steno Diabetes Center Copenhagen and University of Copenhagen
Department of Clinical Medicine
Herlev
Denmark

Co-author 8

Muthiah Vaduganathan
mvaduganathan@bwh.harvard.edu
Brigham and Women's Hospital and Harvard Medical School
Division of Cardiovascular Medicine
Boston
United States

Co-author 9

Meike Brinker
meike.brinker@bayer.com
Bayer AG
Cardiology and Nephrology Clinical Development
Wuppertal
Germany

Co-author 10

Robert Edfors
Robert.edfors@ki.se
Karolinska Institutet
Department of Clinical Sciences, Danderyd University Hospital, Division of Cardiovascular Medicine
Stockholm
Sweden

Co-author 11

Na Li
linda.li@bayer.com
Bayer Healthcare
Global Clinical Leader
Beijing
China

Co-author 12

Markus F. Scheerer
markus.scheerer@bayer.com
Bayer AG
Medical Affairs and Pharmacovigilance
Berlin
Germany

Co-author 13

Charlie Scott
charlie.scott@bayer.com
Bayer PLC
Clinical Statistics and Analytics
Reading
United Kingdom

Co-author 14

Masaomi Nangaku
mnangaku@m.u-tokyo.ac.jp
The University of Tokyo Graduate School of Medicine
Division of Nephrology and Endocrinology
Tokyo
Japan